Elicio reports complete responses in pancreatic cancer
Elicio Therapeutics (NASDAQ:ELTX) announced promising clinical observations regarding its lead immunotherapy candidate, ELI-002 7P, in the treatment of metastatic mKRAS pancreatic ductal adenocarcinoma (PDAC).


_1423274_640x360_2503910979837-640x360.webp&w=3840&q=75)


-640x360.webp&w=3840&q=75)

_1423249_640x360_2503912515918-640x360.webp&w=3840&q=75)

